NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/10/2025
Voltar para busca
Dado oficial do USPTO
IAMBIC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
08/10/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
25/04/2023
Data de registro
07/10/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/10/2025
Última transação
08/10/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2023-10-00
Primeiro uso no comércio
2023-10-00
Código do desenho
4
Tipo de titular
03
Localização do titular
San Diego, CA
Examinador
SOBRAL,CHRISTINA
Unidade examinadora
L90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
IAMBIC THERAPEUTICS, INC.
IAMBIC THERAPEUTICS, INC.
Entos, Inc.
Representantes
Alyssa M. Worsham WILSON SONSINI GOODRICH & ROSATI
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
research and development in the field of computational biologybioinformaticsgenomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceuticalmedicalscientificbiotechnologybiopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; scientific and technological servicesresearch and design in the field of computational chemistrymachine learning and artificial intelligence for use in chemistrybiologyphysicsbiochemistrychemical engineeringcomputer sciencedesign and optimization of moleculesmaterialsdrugs; chemistry serviceslaboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drugmolecular discovery servicesproduct development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drugmaterialsmolecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistrybiologyphysicsbiochemistrychemical engineeringcomputer sciencethe discovery of new moleculesmaterialsdrugsmachine learning techniques; computer programming in the fields of molecularmaterialsdrug development; computer consultancy services being computer software consultation in the field of drugmaterialsmolecular development; computer software consultation servicesassistance and consulting in connection with the development of computer applicationsdatabases and systems for use in the field of drugmaterialsmolecular development; consulting services in the design and implementation of computer-based information systems for businessprovision of online information relating to computer hardware and software design in the field of drugmaterialsmolecular development; creationmaintenancehostingdesign of websites in the field of drugmaterialsmolecular development; provision of online non-downloadable software for simulations for drugmaterialsmolecular discovery; software as a service (SAAS) services featuring computer software platforms for use in optimizing drugmaterialsmolecular discovery; platform as a service (PAAS) featuring computer software platforms for use in optimizing drugmaterialsmolecular discovery; creating website based indexes of information for others using information technology for use in the field of drugmaterialsmolecular development; computer graphics design servicesrealization of computer graphics and digital imaging for use in the field of drugmaterialsmolecular development; scientific research in connection with computerized automation of technical processes for use in the field of drugmaterialsmolecular development; software as a services (SAAS) services in the nature of hosting cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering moleculesdrugsbattery materialsother molecular products
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
07/10/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/10/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
16/09/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
16/09/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
16/09/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
16/09/2025
IUAF
USE AMENDMENT FILED
23/04/2025
EISU
TEAS STATEMENT OF USE RECEIVED
23/04/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
17/12/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/11/2024
PUBO
PUBLISHED FOR OPPOSITION
05/11/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
16/10/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
25/09/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/09/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/09/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
16/07/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
16/07/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
17/04/2024
GNRT
NON-FINAL ACTION E-MAILED
17/04/2024
CNRT
NON-FINAL ACTION WRITTEN
17/04/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/04/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/04/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/04/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
23/01/2024
GNRT
NON-FINAL ACTION E-MAILED
23/01/2024
CNRT
NON-FINAL ACTION WRITTEN
23/01/2024
DOCK
ASSIGNED TO EXAMINER
23/01/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
28/06/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
23/05/2023
NWAP
NEW APPLICATION ENTERED
28/04/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace IAMBIC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.